Healthcare payers want more information about new pharma products’ outcomes sooner than ever. Baker Tilly’s Darren Jones talks with PM360 Magazine about how pharmaceutical companies should make a long-term commitment to measuring outcomes as early as possible to provide the real-world evidence payers are seeking and drive commercial success.